5-Minute Summary: Cost Analysis of Orthopaedic Tumor Treatment: A Comprehensive Review

The economic burden of cancer is substantial, particularly within orthopaedic oncology, where metastatic bone (MBD) imposes significant cost-efficiency challenges on healthcare systems. As a major component of bone disease in cancer, MBD contributes greatly to overall costs and impacts value-based care efforts. MBD is prevalent in 60-84% of patients with metastatic cancer, leading to increased medical expenses and hospitalization costs due to skeletal-related events (SREs). Direct costs associated with orthopedic tumor surgeries are considerable, encompassing inpatient and outpatient care, medication, and long-term follow-up.